Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Viking Therapeutics, Inc....
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 111 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.